Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

Arcturus’ COVID-19 Vaccine Phase 3 Study Shows Promising Results
Arcturus’ COVID-19 Vaccine Phase 3 Study Shows Promising Results
San Diego, Calif.-based Arcturus Therapeutics said that its messenger RNA (mRNA) vaccine has demonstrated strong protection against COVID-19 in a large late-stage study. ...
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, today announced that the U.S. Food and Drug Admini...
Axsome agrees to post-marketing commitments with FDA, signaling potential OK for long-delayed depression drug
Axsome agrees to post-marketing commitments with FDA, signaling potential OK for long-delayed depression drug

Axsome Therapeutics is likely on the cusp of its first drug approval, sending shares of its stock up more than 40% pre-market on Tuesday.

Enzyvant to build regenerative medicine manufacturing plant
Enzyvant to build regenerative medicine manufacturing plant
Enzyvant, which focuses on developing regenerative medicines for rare diseases, has laid out plans to build a new manufacturing facility in the Research Triangle Park area of North Carolina. ...
FDA Grants Fast Track Designation to ADI-001 in Relapsed/Refractory Non-Hodgkin Lymphoma
FDA Grants Fast Track Designation to ADI-001 in Relapsed/Refractory Non-Hodgkin Lymphoma
The FDA has granted a fast track designation to the CAR T-cell therapy ADI-001 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma. ...
AbbVie Pulls Plug on Parkinson’s Partnership With BioArctic
AbbVie Pulls Plug on Parkinson’s Partnership With BioArctic
AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson's disease and other movement disorders. ...
Investigators Release Results of 4 Trials of Immunotherapy Drugs
Investigators Release Results of 4 Trials of Immunotherapy Drugs

Analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.

European Commission Gives Nod to Astellas and Seagen’s Padcev for Urothelial Cancer
European Commission Gives Nod to Astellas and Seagen’s Padcev for Urothelial Cancer
The European Commission has approved Astellas Pharma’s and Seagen’s antibody drug conjugate, Padcev (enfortumab vedotin), for the treatment of adults with locally advanced or metastatic urothel...
FDA Approves Amneal’s Avastin Biosimilar
FDA Approves Amneal’s Avastin Biosimilar

The FDA has approved Amneal Pharmaceuticals’ Alymsys (bevacizumab-maly) as a biosimilar of Roche’s blockbuster cancer drug Avastin.

BioXcel Ascends On $260 Mln Strategic Funding Pact, Creation Of OnkosXcel Therapeutics
BioXcel Ascends On $260 Mln Strategic Funding Pact, Creation Of OnkosXcel Therapeutics
BioXcel Therapeutics, Inc. (BTAI) shares are gaining more than 7 percent on Tuesday morning trade after the company announced strategic financing agreements with Oaktree and Qatar Investment Author...
TG Therapeutics pulls BLA/sNDA for U2 in CLL and SLL and sale of Ukoniq
TG Therapeutics pulls BLA/sNDA for U2 in CLL and SLL and sale of Ukoniq
US biotech TG Therapeutics (Nasdaq: TGTX) saw its shares plunge almost 32% to $6.03, after it announced the voluntary withdrawal of the pending Biologics License Application (BLA)/supplemental New ...
Two strains of TB bacterium attack the lungs in completely different fashion, study finds
Two strains of TB bacterium attack the lungs in completely different fashion, study finds
Two strains of the bacterium causing tuberculosis have only minor genetic differences but attack the lungs in completely different fashion, according to Rutgers researchers. ...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand